OncoMatch/Clinical Trials/NCT04842162
Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery
Is NCT04842162 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies indocyanine green for head and neck cancer.
Treatment: indocyanine green — Assess the sensitivity of real-time near-infrared fluorescence imaging to detect microscopic residual disease in the operating room after a complete macroscopic surgical resection of head and neck cancers
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Cannot have received: radiation therapy
Lab requirements
Kidney function
Advanced renal failure (creatinine > 1.5mg/dL) [excluded]
Cardiac function
Documented coronary artery disease [excluded]
Advanced renal failure (creatinine > 1.5mg/dL) [excluded]; Documented coronary artery disease [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT04842162 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior radiation therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages